Switch theme
Sign up to access all valuation multiples
Yantai Dongcheng Biochemicals Co Ltd is a biochemical analytical profile index (API) manufacturers in China. In addition, the company also focuses on the development of finished preparation which covers the therapeutic area of cardiovascular, oncology, orthopedics, and anti-infection. Its product offering includes heparin sodium, chondroitin sulfate, marine collagen, hyaluronic acid, glucosamine, heparinoids, and cytochrome C. The company's API products have been exported to more than fifty countries and regions, including the United States of America, Germany, Austria, and Japan.
1998
n/a
LTM Revenue $409M
LTM EBITDA $81.7M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Yantai Dongcheng has a last 12-month revenue of $409M and a last 12-month EBITDA of $81.7M.
In the most recent fiscal year, Yantai Dongcheng achieved revenue of $395M and an EBITDA of $66.2M.
Yantai Dongcheng expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Yantai Dongcheng valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $395M | $398M | XXX | XXX | XXX |
| Gross Profit | $212M | $202M | XXX | XXX | XXX |
| Gross Margin | 54% | 51% | XXX | XXX | XXX |
| EBITDA | $66.2M | $79.5M | XXX | XXX | XXX |
| EBITDA Margin | 17% | 20% | XXX | XXX | XXX |
| Net Profit | $42.3M | $28.9M | XXX | XXX | XXX |
| Net Margin | 11% | 7% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Yantai Dongcheng's stock price is CNY 14 (or $2).
Yantai Dongcheng has current market cap of CNY 11.8B (or $1.6B), and EV of CNY 11.7B (or $1.6B).
See Yantai Dongcheng trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.6B | XXX | XXX | XXX | XXX | $0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Yantai Dongcheng has market cap of $1.6B and EV of $1.6B.
Yantai Dongcheng's trades at 3.9x LTM EV/Revenue multiple, and 19.7x LTM EBITDA.
Analysts estimate Yantai Dongcheng's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Yantai Dongcheng and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 20.3x | XXX | XXX | XXX |
| P/E | 61.3x | XXX | XXX | XXX |
| P/E/Growth | 1.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpYantai Dongcheng's NTM/LTM revenue growth is 11%
Yantai Dongcheng's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Yantai Dongcheng's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Yantai Dongcheng's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Yantai Dongcheng and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 31% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 33% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yantai Dongcheng acquired XXX companies to date.
Last acquisition by Yantai Dongcheng was XXXXXXXX, XXXXX XXXXX XXXXXX . Yantai Dongcheng acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Yantai Dongcheng founded? | Yantai Dongcheng was founded in 1998. |
| Where is Yantai Dongcheng headquartered? | Yantai Dongcheng is headquartered in China. |
| Is Yantai Dongcheng publicy listed? | Yes, Yantai Dongcheng is a public company listed on SHE. |
| What is the stock symbol of Yantai Dongcheng? | Yantai Dongcheng trades under 002675 ticker. |
| When did Yantai Dongcheng go public? | Yantai Dongcheng went public in 2012. |
| Who are competitors of Yantai Dongcheng? | Similar companies to Yantai Dongcheng include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Yantai Dongcheng? | Yantai Dongcheng's current market cap is $1.6B |
| What is the current revenue of Yantai Dongcheng? | Yantai Dongcheng's last 12-month revenue is $409M. |
| What is the current EBITDA of Yantai Dongcheng? | Yantai Dongcheng's last 12-month EBITDA is $81.7M. |
| What is the current EV/Revenue multiple of Yantai Dongcheng? | Current revenue multiple of Yantai Dongcheng is 3.9x. |
| What is the current EV/EBITDA multiple of Yantai Dongcheng? | Current EBITDA multiple of Yantai Dongcheng is 19.7x. |
| What is the current revenue growth of Yantai Dongcheng? | Yantai Dongcheng revenue growth between 2023 and 2024 was 1%. |
| Is Yantai Dongcheng profitable? | Yes, Yantai Dongcheng is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
